Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
826 stopped studies mapped to Malignant Female Reproductive System Neoplasm and descendants · 86% state a reason
Over the 826 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04814875 | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | Phase 1 / Phase 2 | terminated | Mar 24, 2021 | THERAPIM PTY LTD | For technical reasons, it was decided by the sponsor to close the ongoing ovarian cancer study, AM… | Other (stated, no rule matched) |
| NCT04460807 | Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer(EXPERT) | Phase 3 | terminated | Jul 8, 2020 | Ente Ospedaliero Ospedali Galliera | low accrual, COVID 19 emergency and the modification of the standard of care for ovarian cancer… | COVID-19 / pandemic |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT03606486 | Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer | N/A | terminated | Jul 30, 2018 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants… | Phase 1 / Phase 2 | terminated | Jun 20, 2019 | pharmaand GmbH | Due to a change in development priorities, no further clinical development of the lucitanib plus… | Other (stated, no rule matched) |
| NCT04864782 | QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical… | Phase 2 / Phase 3 | terminated | Apr 29, 2021 | Qilu Pharmaceutical Co., Ltd. | Phase 2 completed, phase 3 sponsor decided to terminate | Sponsor / business decision |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug… | Phase 1 / Phase 2 | terminated | May 11, 2017 | CytomX Therapeutics | Covid Pandemic; Business Decision to separate Phase 2 to new study | COVID-19 / pandemic |
| NCT03858166 | Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration… | Phase 4 | terminated | Feb 28, 2019 | Shandong University | Sponsor Termination | Other (stated, no rule matched) |
| NCT04970368 | Comparison of Nodal Staging in Endometrial Cancer | Phase 3 | terminated | Jul 21, 2021 | Frederick R. Ueland, M.D. | Slow accrual | Enrollment / accrual |
| NCT04999605 | A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Akeso | Too low inclusion rate | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT04267939 | ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid… | Phase 1 | terminated | Feb 13, 2020 | Bayer | There was no anticipated benefit of the experimental combination as tested over available standard… | Other (stated, no rule matched) |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
| NCT00250016 | Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) | — | withdrawn | Nov 7, 2005 | University of New Mexico | UNM did not proceed with research | Other (stated, no rule matched) |
| NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and… | Phase 1 | terminated | Jan 7, 2016 | SCRI Development Innovations, LLC | Clinical program was discontinued by Novartis | Other (stated, no rule matched) |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus… | Phase 1 | terminated | Mar 4, 2019 | Leap Therapeutics, Inc. | Product development discontinued unrelated to safety. | Safety / toxicity |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer… | N/A | terminated | Aug 22, 2018 | University of Washington | Enrollment ended early due to the funding timeline | Enrollment / accrual |
| NCT03694834 | Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer | Early Phase 1 | terminated | Oct 3, 2018 | UNC Lineberger Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT03412630 | Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With… | N/A | terminated | Jan 26, 2018 | ECOG-ACRIN Cancer Research Group | poor accrual | Enrollment / accrual |
| NCT03735589 | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells)… | Phase 1 / Phase 2 | withdrawn | Nov 8, 2018 | Roswell Park Cancer Institute | new study to be created | Other (stated, no rule matched) |
| NCT05998941 | A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the… | Phase 2 | withdrawn | Aug 21, 2023 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Slow progress in development, the sponsor decided to withdraw and no longer proceed. | Sponsor / business decision |
| NCT03944902 | CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer…(BRCA) | Phase 1 | terminated | May 10, 2019 | University of Alabama at Birmingham | will not resume. company choosing not to continue with drug. one participant now off study. | Sponsor / business decision |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT02432690 | A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation | Phase 2 | terminated | May 4, 2015 | Sumitomo Pharma America, Inc. | not stated | Not stated |
| NCT05905341 | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in… | Phase 1 | withdrawn | Jun 15, 2023 | Pfizer | This decision was based on business considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT02834975 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial… | Phase 2 | terminated | Jul 15, 2016 | University of Miami | Investigator left institution | Investigator |
| NCT05332483 | Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer(MA-EEC) | Phase 1 | terminated | Apr 18, 2022 | Sunnybrook Health Sciences Centre | Slow enrollment | Enrollment / accrual |
| NCT05712941 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients… | Phase 3 | withdrawn | Feb 6, 2023 | EQRx International, Inc. | The study is being closed based on corporate changes at EQRx and is not related to any efficacy or… | Safety / toxicity |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous… | Phase 3 | terminated | May 9, 2013 | Pfizer | Per recommendation of the DMC, enrollment into the study was discontinued in April 2016 after the… | Efficacy / futility |
| NCT04729608 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With…(AXLerate-OC) | Phase 3 | terminated | Jan 28, 2021 | Aravive, Inc. | There were no significant differences in median PFS between batiraxcept + paclitaxel or paclitaxel… | Safety / toxicity |
| NCT01041027 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk… | Phase 2 | terminated | Dec 30, 2009 | Albert Einstein College of Medicine | Due to slow accrual. Results from the PORTEC3 the study rendered the hypothesis no longer valid. | Enrollment / accrual |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | Phase 3 | terminated | Apr 15, 2022 | Mersana Therapeutics | Study Terminated by Sponsor | Other (stated, no rule matched) |
| NCT00180739 | Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women… | Phase 4 | withdrawn | Sep 16, 2005 | Imperial College London | Recruitment not possible worldwide | Enrollment / accrual |
| NCT05466916 | EDITS Pilot Study for Gynecologic Cancer Survivors | N/A | withdrawn | Jul 20, 2022 | Rutgers, The State University of New Jersey | Study was never initiated and no participants were enrolled. | Enrollment / accrual |
| NCT04598321 | BrUOG 390: Neoadjuvant Treatment With Talazoparib | Phase 1 | terminated | Oct 22, 2020 | Brown University | termination of research grant agreement | Other (stated, no rule matched) |
| NCT04511026 | Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in… | Phase 2 | terminated | Aug 12, 2020 | Stanford University | Efficacy | Efficacy / futility |
| NCT04907968 | Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With…(UPGRADE) | Phase 1 | terminated | Jun 1, 2021 | Mersana Therapeutics | Study Terminated by Sponsor | Other (stated, no rule matched) |
| NCT04891185 | Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer(VIPIDO) | Phase 2 | terminated | May 18, 2021 | Universitaire Ziekenhuizen KU Leuven | Clinical futility | Efficacy / futility |
| NCT00006099 | Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian… | Phase 1 | terminated | Dec 23, 2003 | Ludwig Institute for Cancer Research | low study accrual | Enrollment / accrual |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating… | Phase 2 | terminated | Sep 3, 2008 | M.D. Anderson Cancer Center | The trial was stopped early because there was only one patient with pCR among the first 15 patients… | Other (stated, no rule matched) |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and… | Phase 2 | withdrawn | Mar 25, 2022 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Phase 1 | terminated | May 27, 2022 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT01076400 | A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants… | Phase 1 / Phase 2 | terminated | Feb 26, 2010 | Merck Sharp & Dohme LLC | The sponsor permanently suspended new enrollment into the trial and discontinued the study; which… | Safety / toxicity |
| NCT05201001 | APX005M in Patients With Recurrent Ovarian Cancer(APX005M) | Phase 2 | withdrawn | Jan 21, 2022 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | IMP provider company (Apexigen) is sold, thus both IMP and grant is terminated | Sponsor / business decision |
| NCT03302156 | PSMA PET and MRI in Gynecological Cancers | Phase 2 | terminated | Oct 4, 2017 | University of Wisconsin, Madison | Slow accrual following suspension per COVID-19 | COVID-19 / pandemic |
| NCT02112552 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating… | Phase 2 | terminated | Apr 14, 2014 | Albert Einstein College of Medicine | Low accrual. Study formally terminated by PI on 12/1/2017 | Enrollment / accrual |
| NCT01367301 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer | N/A | terminated | Jun 7, 2011 | Albert Einstein College of Medicine | Lack of accrual. PI left the institution | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 14, 2024source: clinicaltrials